The PennZone

  • Home
  • Non-profit
  • Business
  • Education
  • Entertainment
  • Technology
  • Construction
  • Celebrities
  • Travel

HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
The PennZone/10270943

Trending...
  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph
  • Bishop Mary's WWDB 860 AM Show Nears Historic 250-Episode Milestone
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.

The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.

More on The PennZone
  • Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon
  • The Hardest Part of Building an App Isn't Starting - It's Finishing
  • Imagen Golf Revolutionizes Instruction with "The Pronto Lesson,"
  • Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
  • Legacy of Learning Benefit to Support Scholarships at Grace Montessori School

The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.

HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
  • Spring Into Your New Home at Heritage at South Brunswick
  • ULiveUSA Launches New "Moment Marketing" System Using Videos to Help Local Businesses Get More Customers
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • HarryPotterObamaSonic10Inu (Ticker: BITCOIN) Is the Best Cryptocurrency in Global History
  • Colonial Nissan Highlights 2026 Armada after Major Best Buy Award Win
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph
  • Additions of Tennant, Morrissey, Cummings, Hale Highlight Fandoms at FAN EXPO Philadelphia
  • GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
  • 5 Things to Check Before Calling for AC Repair in Philly
  • Go Dental Clinic Announces Upcoming Opening of New Branch in International City, Dubai
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Hazel E Hosts Starline Tours Bus to Sonic Desert - A Launch to Coachella
  • Best Companies Group Launches Free Top Companies to Work for in Arizona Program
  • A Powerful Beginning Inside One of Philadelphia's Most Inspiring Early Childhood Education Centers
  • A1 OM Ads LLC Expands Platform With AI Tools And Digital Marketing Solutions
  • Streater Appointed to Judicial Commission of the Philadelphia Bar Association
  • Contracting Resources Group and Aalis Management Consulting Launch ARG Joint Venture Under SBA Mentor-Protégé Program
  • Space Opera Debut Earns Prometheus Award Nomination

Popular on PennZone

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 252
  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion - 125
  • 300 Episodes. One Mission: Brother Marcus Ignites a Global Movement of Inspiration - 102
  • R&B Artist Mike Davis Announces Debut Full-Length Album Full Circle, Releasing April 7
  • Bethany Nikitenko Elected Board Vice President of Philadelphia VIP
  • From Speech Therapy to 300+ Episodes: Brother Marcus Turns His Voice Into a Movement Launching a 24/7 Inspiration Radio Network on Day 100 of the Year
  • The Finger Comb, a Dream Inspired 3-in-1 Styling Tool introduced by Andrea L. Randolph
  • Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
  • Porter's Day Care Empowers Philadelphia's Future Through 45+ Years of Excellence
  • Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming

Similar on PennZone

  • Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon
  • Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
  • ULiveUSA Launches New "Moment Marketing" System Using Videos to Help Local Businesses Get More Customers
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Dog Grooming Businesses Turn to Performance-Based Platforms to Attract Local Clients
  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BestDoc Launches AI Call Center for Healthcare
  • Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us